American Diabetes Association

Figure 4—

$Relationship between initial fractional reduction in insulin output and corresponding diabetes incidence rates during drug treatment in the troglitazone arm of the TRIPOD study (•, median duration of treatment = 31 months) and in the PIPOD study (▪, median duration of treatment = 35 months). Insulin output was assessed as the total area under the insulin curve during 4-h, tolbutamide-modified intravenous glucose tolerance tests. Reductions in insulin output were calculated between enrollment into each study and the initial on-treatment IVGTT, which occurred after 3 months in TRIPOD and after 1 year in PIPOD. Symbols represent the low, middle, and high tertile of change in each study. Lines represent best linear fits of data for each study. Reproduced from Xiang et al. (36).$

Relationship between initial fractional reduction in insulin output and corresponding diabetes incidence rates during drug treatment in the troglitazone arm of the TRIPOD study (•, median duration of treatment = 31 months) and in the PIPOD study (▪, median duration of treatment = 35 months). Insulin output was assessed as the total area under the insulin curve during 4-h, tolbutamide-modified intravenous glucose tolerance tests. Reductions in insulin output were calculated between enrollment into each study and the initial on-treatment IVGTT, which occurred after 3 months in TRIPOD and after 1 year in PIPOD. Symbols represent the low, middle, and high tertile of change in each study. Lines represent best linear fits of data for each study. Reproduced from Xiang et al. (36).

This Feature Is Available To Subscribers Only